Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"


News provided by

Hanmi Pharmaceutical

29 Jun, 2021, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

Large-scale phase 3 trial shows significant reduction in cardiovascular and kidney disease risk

First public reveal of results from large-scale, Sanofi-led global phase 3 trial for efpeglenatide

Hanmi aims to achieve new innovations with biologic

SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the results of its global, large-scale clinical trial with more than 4,000 patients.

Continue Reading
This image opens in the lightbox
Main speakers and topics of Sanofi’s “Independent Session on Efpeglenatide”

According to Hanmi, Sanofi presented the results of the global, large-scale cardiovascular clinical trial (AMPLITUDE-O) at the "Independent Session on Efpeglenatide", which was held at the American Diabetes Association (ADA) Scientific Sessions on June 29th. During this two-hour session,  Dr. Hertzel Gerstein and seven other researchers presented on eight different topics, respectively, regarding the results from AMPLITUDE-O.

The AMPLITUDE-O phase 3 clinical trial included 4,076 patients with Type 2 diabetes or cardiovascular disease across 344 regions in 28 countries. For the purpose of this trial, either 4mg or 6mg of efpeglenatide or a placebo was administered to patients on a weekly basis.

According to the results, the risk of cardiovascular and kidney disease was significantly reduced in Type 2 diabetes patients who received the 4 mg and 6 mg doses of efpeglenatide. When compared to the placebo group, there was a 27% incidence rate of major cardiovascular diseases [HR: Hazard Ratio 0.73, 95%, confidence interval (CI: confidence interval 0.58 – 0.92)] and a 32% incidence rate of kidney disease (HR 0.68, 95% CI 0.57 - 0.79) in the efpeglenatide group, thus statistically demonstrating that the drug significantly decreases incidences of such diseases.

Naveed Sattar(University of Glasgow, MD, Ph.D.) said "The Amplitude-O trial shows that efpeglenatide safely reduces major cardiovascular and renal outcomes in low and high risk people with type 2 diabetes while lowering glucose, blood pressure and weight"

Seungjae Baek (MD, Ph.D.), Chief Medical Officer at Hanmi, highlighted the promising implications of this study's results. Baek shared, "I would like to think that efpeglenatide has provided us with a new opportunity to achieve innovation in other ways. We are focusing our capacities on expanding upon and realizing the potential of efpeglenatide, whose efficacy has been demonstrated through large-scale, global phase 3 clinical trials."

Efpeglenatide is a once-weekly GLP-1 receptor agonist drug that was developed by Hanmi for the treatment of diabetes mellitus and was licensed out to Sanofi in 2015. Last year, Sanofi returned the rights of efpeglenatide due to changes in the company's business strategy. As such, the rights currently belong to Hanmi.

At this year's ADA meeting, Hanmi also presented the results of another study on the efficacy and safety of efpeglenatide in Type 2 diabetes patients. Lead researcher Dr. Juan Frias presented the results of this study, which involved another global phase 3 clinical trial (AMPLITUDE-M) with 406 Type 2 diabetes patients whose blood sugar could not be managed through diet and exercise.

This study was conducted as a double-blind clinical trial over the course of 56 weeks, with the efpeglenatide group being divided into three subgroups by dosage (2mg, 4mg, and 6mg). The primary endpoint of the trial was glycated hemoglobin (HbA1c) levels at the 30th week. At the 56th week of the trial, HbA1c levels, weight loss, and safety of the efpeglenatide were compared, respectively, with those of the placebo group.

The results of the study confirmed excellent blood sugar control and weight loss when efpeglenatide was administered to Type 2 diabetes patients, and the effects of the treatment were maintained for an extended period of time. At 30 weeks of treatment, when compared to the placebo group, patients across all dosage groups of efpeglenatide showed statistically significant improvement in HbA1c levels compared to those of the placebo group. Patients in the 4mg and 6mg dosage groups also showed significant weight loss. Positive effects of the treatment, such as blood sugar management and weight loss, remained stable for 56 weeks. Reported side effects among participants included mild to moderate diarrhea and nausea.

Furthermore, at the ADA meeting, Hanmi announced the results of four preclinical studies, including its study on LAPSGlucagon Analog, a long-acting glucagon-like peptide analog. Hanmi plans to share major ADA announcements on its website.

Se Chang Kwon, President and CEO of Hanmi Pharmaceutical, noted, "Considering that drugs currently sold on the global market for metabolic diseases often possess the risk of cardiovascular disease following long-term observations, cardiovascular safety is crucial in strengthening a given drug's global competitiveness. With the demonstration of efpeglenatide's safety regarding the risk of cardiovascular disease, as demonstrated in this large-scale clinical trial, we have found new business opportunities for innovation."

The clinical outcomes of efpeglenatide published on, a leading international journal, New England Journal of Medicine (NEJM).

Photo - https://mma.prnewswire.com/media/1553724/photo1.jpg

Modal title

Also from this source

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi...

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Biotechnology

Biotechnology

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.